rh-bFGF Ocular Composition for Dry Eye Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for dry eye, such as sodium hyaluronate and polyvinyl alcohol eye drops, only provide temporary relief and can cause ocular surface damage due to preservatives, and there is no product using human-derived basic fibroblast growth factor (bFGF) for treating dry eye.
Innovation Solution
A pharmaceutical composition comprising recombinant human-basic fibroblast growth factor (rh-bFGF) combined with stabilizers like glycine, histidine, arginine, Tween, heparin sodium, or human serum albumin, which is preservative-free and formulated for ocular administration to treat dry eye.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If preservatives are added to eye drop formulations to prevent contamination, then product stability and shelf life are improved, but ocular surface damage and severity of eye diseases increase
Solution Approach 1:
The patent removes preservatives from the eye drop formulation entirely, extracting the harmful component while maintaining product stability through alternative means (sterile manufacturing processes and stable formulation chemistry), thereby eliminating ocular surface damage without sacrificing reliability
Solution Approach 2:
The patent employs single-use or frequently replaced sterile packaging systems that eliminate the need for preservatives, allowing each unit to remain preservative-free while maintaining sterility through disposable containment, thus avoiding preservative-induced ocular damage
2Ease of operation
If artificial tears are used to treat dry eye symptoms, then temporary relief is provided, but they cannot replace natural tear function and provide sustained relief
Solution Approach 1:
The patent introduces bFGF as a biological mediator that actively promotes tear gland function and ocular surface healing, transforming the formulation from passive lubrication (artificial tears) to active physiological restoration, thereby extending duration of action and providing sustained relief
Solution Approach 2:
The patent changes the formulation from simple lubricants to a biologically active composition containing bFGF at optimized concentrations, altering the mechanism of action from physical coating to biological stimulation, thereby extending duration of relief and improving therapeutic efficacy
3Reliability
If the natural tear film structure is attempted to be replicated, then functional effectiveness is improved, but formulation complexity increases
Solution Approach 1:
The patent segments the complex natural tear film into its essential functional components (lubricants, electrolytes, and bFGF), formulating only the critical elements needed for therapeutic effect rather than attempting to replicate the entire complex structure, thereby maintaining functionality while reducing formulation complexity
Data Source
AI summary
Provided are a mutated nucleic acid molecule of a recombinant human-basic fibroblast growth factor (rh-bFGF), a pharmaceutical composition of the rh-bFGF, and a use thereof.